Tom was previously an Executive-in-Residence of the Samuel Zell & Robert H. Lurie Institute for Entrepreneurial Studies at the University of Michigan where he taught a class on managing the growth of new ventures at the Ross School and manages the School’s student-led Frankel Commercialization Fund, a seed and pre-seed venture capital fund having teams investing in Technology, Healthcare, Cleantech, and Consumer products.
Previously, Tom co-founded and is a former general partner in EDF Ventures, an Ann Arbor-based venture capital firm investing in early-stage companies in healthcare and information technology. At EDF he lead the healthcare practice where he founded five companies based on technology from Michigan universities: Theragen Inc.(now GENVEC, GNVC on NASDAQ), Coagulation Systems Inc., Selective Genetics Inc., IntraLase Corp. (purchased by Abbott following a successful IPO), and HandyLab Inc. (purchased by Becton Dickinson), creating more than $1 billion in exit values for investors.
Tom currently serves as the chairman of Incept Biosystems and Better Rehab LLC., companies which he also founded or co-founded, and works with universities and research institutions that are engaged in the commercialization of technology. He founded and served as chairman of the Van Andel Institute’s technology advisory board, and currently serves as a member of U-M’s national technology transfer advisory board and Vice Chair of the Council of Michigan Foundations.
Tom holds an MBA from the University of Michigan Ross School of Business and a BA from DePauw University where he is a member of the Board of Visitors.